Abstract 474P
Background
We investigated KCNJ11 expression in different glioma tissue subtypes and its use as a predictor of glioma prognosis and sensitivity to temozolomide chemotherapy and determined the value of performance evaluation indicators.
Methods
Data on sex, age, histopathological type, WHO grade, IDH mutation, 1p/19q deletion, survival time, and KCNJ11 mRNA were collected from 516 patients with glioma. Expression levels and other data and uni- and multivariate Cox regression analyses were used to determine prognostic factors for patients with glioma. Data obtained from 603 cases with different glioma subtypes in TCGA database, 284 cases in REMBRANDT, and 264 cases in the United States database of the National Center for Biotechnology Information were verified to correlate KCNJ11 mRNA expression levels with the relationship between different clinical features and overall survival.
Results
KCNJ11 mRNA expression in 516 patients with different glioma subtypes correlated with histopathological type, WHO grade, IDH mutation status, 1p/19q co-deletion status, MGMT methylation, and WHO molecular classification (both P<0.05). Median survival times in the high KCNJ11 mRNA expression group were longer than those in the low expression group (P<0.05). Multivariate Cox regression analysis showed that age, tumor recurrence, WHO classification, IDH mutation, 1p/19q co-deletion, postoperative chemotherapy, and KCNJ11 mRNA expression were independent influencing factors of overall patient survival time. In the TCGA dataset, median overall survival times in the high expression group were longer than those in the low expression group (P<0.05). In the REMBRANDT dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05). In the GSE1101 dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05).
Conclusions
KCNJ11 mRNA expression was related to the degree of tumor malignancy and was an independent factor affecting overall survival time, and overall survival times of patients with high KCNJ11 mRNA expression are longer than those of patients with low KCNJ11 mRNA expression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
K. Zhou.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
469P - Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial
Presenter: Marie Porte
Session: Poster session 16
470P - Mitochondrial ribosomal proteins (MRPs) in glioblastoma multiforme: Omics approach
Presenter: Jehad Yasin
Session: Poster session 16
471P - PTEN alteration as a predictor of second-line efficacy in patients with recurrent IDHwt-glioblastoma
Presenter: Eugenia Cella
Session: Poster session 16
472P - Comprehensive quinomics assessment of BPM31510IV treatment in advanced glioblastoma multiforme patients
Presenter: Seema Nagpal
Session: Poster session 16
473P - A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)
Presenter: Maurizio Polano
Session: Poster session 16
475P - Optimising genomic testing for patients with central nervous system (CNS) tumours using oxford nanopore technology
Presenter: Alona Sosinsky
Session: Poster session 16
476P - The role of androgen receptor expression and epigenetic regulation in adult-type diffuse gliomas
Presenter: VINCENZO DI NUNNO
Session: Poster session 16
477P - ENHO's protective role in lower grade glioma
Presenter: Osama Younis
Session: Poster session 16
478P - Molecular characterization of adult non-glioblastoma central nervous system (CNS) tumors to identify potential targettable alterations
Presenter: Marta Padovan
Session: Poster session 16